MAR 10, 2015 9:00 AM PDT

Newly Updated Guidelines for the Diagnosis of Multiple Myeloma

Sponsored by: Binding Site, Binding Site
Speakers
  • Professor of Medicine & Chief of Multiple Service at Memorial Sloan-Kettering in New York City
    Biography
      Dr. Landgren is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at MSKCC designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. Dr. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop of treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.

      Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.

    Abstract:
    DATE: Tuesday, March 10, 2015
    TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMT


    The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

    The updated criteria, published in The Lancet Oncology represent a significant change in how Multiple Myeloma is diagnosed and the stage at which patients should be treated.

    Join us on March 10th on a webinar covering these updated criteria for Myeloma and related plasma cell disorders and the importance of biomarkers in Early Stage Disease.
    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
    Following this presentation the listener will:
    • Understand the history and traditional tools used to diagnose Myeloma
    • Gain an appreciation for the evolution of Myeloma diagnosis and biomarkers of the disease
    • Be able to understand how to apply the new diagnostic guidelines to the diagnosis and treatment of Myeloma.

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    NOV 21, 2019 9:00 AM PST
    C.E. CREDITS
    NOV 21, 2019 9:00 AM PST
    DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources